1 / 9

Sofosbuvir in Genotypes 2 or 3 VALENCE Trial

This study evaluates the efficacy of sofosbuvir and ribavirin in the treatment of hepatitis C genotypes 2 or 3. The results show high sustained virologic response rates in both treatment-naïve and treatment-experienced patients.

ingramj
Download Presentation

Sofosbuvir in Genotypes 2 or 3 VALENCE Trial

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phase 3 Treatment Naïve and Treatment Experienced Sofosbuvir in Genotypes 2 or 3VALENCE Trial Zeuzem S, et al. N Engl J Med. 2014;370:1993-2001

  2. Sofosbuvir and Ribavirin for HCVGT 2 or 3VALENCE Trial: Study Features Source: Zeuzem S, et al. N Engl J Med. 2014;370:1993-2001.

  3. Sofosbuvir and Ribavirin for HCV GT 2 or 3VALENCE: Treatment Arms 0 12 24 36 Week GT 2 Sofosbuvir +RBV(n = 73) SVR12 GT 3 Sofosbuvir +RBV(n = 250) SVR12 Note: 85 patients enrolled in placebo arm Original Study Protocol: Placebo versus 12 weeks treatment for GT 2 and 3. Amended Protocol: GT3 treatment extended from 12 to 24 weeks; Placebo arm offered alternative treatment Drug DosingSofosbuvir 400 mg once dailyRibavirin (weight-based and divided bid): 1000 mg/day if < 75 kg or 1200 mg/day if ≥ 75 kg Source: Zeuzem S, et al. N Engl J Med. 2014;370:1993-2001.

  4. Sofosbuvir and Ribavirin for HCV GT 2 or 3VALENCE: Results for Treatment Naïve and Experienced VALENCE: SVR12 by Genotype 68/73 213/250 12-week Treatment 24-week Treatment Source: ZeuzemS, et al. N Engl J Med. 2014;370:1993-2001.

  5. Sofosbuvir and Ribavirin for HCV GT 2 or 3VALENCE: Results VALENCE: SVR12 by Genotype and Prior Treatment Experience 68/73 31/32 37/41 213/250 99/105 114/145 Source: Zeuzem S, et al. N Engl J Med. 2014;370:1993-2001.

  6. Sofosbuvir and Ribavirin for HCV GT 2 or 3VALENCE: Results for GT 2 VALENCE: GT 2 SVR12, by Treatment Experience & Liver Disease Treatment-Naive Treatment-Experienced Source: Zeuzem S, et al. N Engl J Med. 2014;370:1993-2001.

  7. Sofosbuvir and Ribavirin for HCV GT 2 or 3VALENCE: Results for GT 3 VALENCE: GT 3 SVR12, by Treatment Experience & Liver Disease 87/92 12/13 85/98 29/47 Treatment-Naive Treatment-Experienced Source: Zeuzem S, et al. N Engl J Med. 2014;370:1993-2001.

  8. Sofosbuvir and Ribavirin for HCV GT 2 or 3VALENCE: Conclusions Source: Zeuzem S, et al. N Engl J Med. 2014;370:1993-2001

  9. This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Onlinewww.hepatitisc.uw.edu Hepatitis Web Studyhttp://depts.washington.edu/hepstudy/ Funded by a grant from the Centers for Disease Control and Prevention.

More Related